Responses
Clinical/translational cancer immunotherapy
Original research
Novel anti-4-1BB×PD-L1 bispecific antibody augments anti-tumor immunity through tumor-directed T-cell activation and checkpoint blockade
Compose a Response to This Article
Other responses
No responses have been published for this article.